Navigation Links
Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
Date:11/2/2011

WALTHAM, Mass., Nov. 2, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that pharmacodynamic analysis in a subset of patients from ENCORE 301, a randomized phase 2 study of exemestane with and without entinostat in advanced breast cancer patients, will be presented in an oral session at the American Association for Cancer Research (AACR) Molecular Targets and Cancer Therapeutics Conference.  

The positive data was from ENCORE 301 (ENtinostat Combinations Overcoming REsistance), a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of exemestane with and without entinostat in 130 postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer, progressing on treatment with the non-steroidal aromatase inhibitors anastrozole or letrozole.  The study which met the primary endpoint of progression free survival (PFS) was presented at the ASCO Breast Cancer Symposium in September earlier this year.  

The pharmacodynamic data will be presented by Peter Ordentlich, Ph.D. in an oral session called the Proffered Paper Session 1 on Sunday, November 13, 2011 from 4:30 to 6:00 PM PT.

For media

The data will be discussed during a press conference on Sunday, November 13, 2011 at 7:30 AM PT in room 2004 of the Moscone Convention Center.  To dial in to the webcast please dial Toll-Free (US & Canada) (888) 647-7462 or International Dial-In (Toll): (201) 604-0169.

Breast Cancer and Hormone Therapy

Annually about 207,000 women have breast cancer in the United States and about 20,000 of them have metastatic breast cancer (MBC).  Approxima
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
2. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
3. MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
4. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
5. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
6. Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences
7. Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference
8. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
9. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
10. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
11. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 genae, a ... industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in the ... it is projected to increase by a CAGR of 6.0% until ... equal to 9.5% of GDP. Despite recessionary pressures, market growth rates ...
(Date:7/31/2014)... 31, 2014 Astellas has appointed ... and employee communications in the Americas region. Knight ... senior vice president, chief communications officer. In this ... leading corporate brand initiatives and reputation management to ... South America . She will ...
(Date:7/31/2014)... -- The Galien Foundation today announced the 2014 nominees ... Awards. The Prix Galien Award is considered ... scientific and clinical research skills necessary to develop innovative ... highest number of nominees since the inception of the ... biomedical products across three categories – biotechnology, pharmaceutical, and ...
Breaking Medicine Technology:genae Opens Offices in London 2Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5
... 5, 2011 SyncMedical LLC today announced ... – Brazilian National Health Surveillance Agency) has approved their ... in Brazil. SyncMedical,s Ethos Spine product line was developed ... treatment solutions to surgeons in the ever-growing, ever-changing field ...
... Jan. 5, 2011 Heska Corporation (Nasdaq: HSKA ... Conference hosted by Sidoti & Company, LLC on Monday, January ... 42nd Street (Park Avenue at Grand Central) in New York ... Eastern Time. (Logo:   http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ...
Cached Medicine Technology:SyncMedical Receives ANVISA Regulatory Approval to Offer Spine and Internal Medicine Products in Brazil 2
(Date:7/31/2014)... July 31, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
(Date:7/31/2014)... Leelanau Peninsula, MI (PRWEB) July 31, 2014 ... in preparation of the upcoming harvest. And, to celebrate, folks ... held Saturday and Sunday, September 6 and 7, 2014 along ... weekend festivities is an optional walk or run through the ... & Winery in Suttons Bay. A unique course between rows ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Cosmetic ... benefit both patients and doctors. Doctors will be able ... to leave reviews , which guarantees their authenticity. ... options on the site to receive information that has ... This unprecedented validation system allows Cosmetic Town to filter ...
(Date:7/31/2014)... 31, 2014 NEWwoodworks, fine woodworking group ... their brand presence with a website dedicated to highlighting ... NEWwoodworks has specialized in handcrafted cabinetry, furniture, stairs ... has earned a reputation for taking on the remarkable, ... They commonly craft with reclaimed wood, often using near ...
(Date:7/31/2014)... US Hair Restoration Founder, Dr. Parsa Mohebi, has recently ... Mohebi Hair Restoration. Since first opening in 2008, US ... and around the world, who traveled to one of its ... patients achieved the full benefits of a variety of hair ... Dr. Mohebi. They have come to understand how his ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:US Hair Restoration Becomes Parsa Mohebi Hair Restoration 2
... GAP, Pa., April 1, 2008 Core People ... Service Corporation,(CCSC) of Wexford, PA. CCSC provides options ... benefits for Pennsylvania chamber members through,its ChamberChoice portfolio., ... to offer a,broader level of employer services, including ...
... Awareness among Hispanic Community as Fewer ... Receiving Diagnosis and Support, CHICAGO, April 1, ... individuals living with autism, among the,vast array of services the national ... the last 20 years, Easter Seals has seen a dramatic increase ...
... rates to that from younger donors , , TUESDAY, April ... 75 should be allowed to donate corneas for transplant, says ... that tissue from donors aged 66 to 75 had the ... aged 12 to 65. , The research, coordinated by the ...
... the pharmaceutical industry currently underway will increase in the ... researcher at the National Institutes of Health (NIH) who ... development. , According to Christopher Austin, M.D., ... industry and academia welcome more cooperation in drug discovery ...
... CHICAGO, Ill. (April 1, 2008) Many patients ... percutaneous coronary intervention (PCI) are already taking 75mg ... Even so, an additional 600-mg reloading dose of ... risk of bleedingbut only in patients with acute ...
... 1, 2008 Senetek PLC (OTC,Bulletin Board: SNKTY), ... technologies that target the science of healthy aging, ... has secured financing in an,amount up to $28 ... of men,s health treatments, including Invicorp(R)., Plethora ...
Cached Medicine News:Health News:Core People Partners to Expand Services 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 3Health News:Study Finds Older Corneas Suitable for Transplantation 2Health News:Business of drug development on verge of great change 2Health News:Clopidogrel reloading worthwhile in acute coronary syndromes 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 3Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: